No Data
Nikkei Edges Lower as Traders Brace for Nvidia Earnings
MediPal Holdings Merges Subsidiaries to Streamline Sales Network, Medical Equipment Business
Chordia Research Memo (1): Advancing the development of potential blockbuster anticancer drugs by a biotech venture that may become a block inc.
Chordia Therapeutics <190A> was founded by drug discovery researchers spun out from takeda pharmaceuticals sp adr <4502>, specializing in the development of small molecule anticancer drugs. The core business ranges from exploratory research to clinical research, with in-house manufacturing and sales through partnership strategies domestically, aiming for early profitability by licensing out overseas. Listed on the Tokyo Stock Exchange Growth Market in June 2024.
Medipal Holdings: Confirmation letter
Medipal Holdings: Semi-Annual Report - 116th Term (2024/04/01 - 2025/03/31)
Sumitomo Electric, Mabuchi, etc. (Additional) Rating
Upgrade - Bullish Code Stock Name Securities Company Previous After Change ---------------------------------- <6080> M&A Capcom Maclory "Under P" "Out P" <6752> Panasonic HD Maclory "Neutral" "Out P" Target Stock Price Change Code Stock Name Securities Company Previous After Change ----------------------------------
No Data
No Data